Table 1.

Baseline characteristics in our cohort of 70 patients with multiple sclerosis treated with ocrelizumab.

Patients	RMS (n = 49)	PPMS (n = 21)
Age at ocrelizumab start	39.2 ± 10.9	47.1 ± 10.5
Sex (Female)	69%	38%
Time since diagnosis (years)	7.7 ± 6.7	2.8 ± 4.1
Baseline EDSS; median (IQR)	2.5 (2–3)	3.0 (3–4.8)
ARR previous year	1.3 ± 0.65	–
Treatment naive n/N (%)	10/49 (20%)	19/21 (90%)
Patients with at least one Gd-enhancing lesions, n/N (%)	31/49 (63%)	9/21 (43%)

ARR, anualized relapse rate; EDSS, Expanded Disability Status Scale; IQR, interquartile range.